On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Broquetas, Teresa
• dc.contributor.author Hernández, Juan José
• dc.contributor.author Garcia-Retortillo, Montserrat
• dc.contributor.author Canillas, Lidia
• dc.contributor.author Puigvehí, Marc
• dc.contributor.author Cañete Hidalgo, Nuria
• dc.contributor.author Coll Estrada, Susanna
• dc.contributor.author Viu, Ana
• dc.contributor.author Garrido, Esther
• dc.contributor.author Micó, Miquel
• dc.contributor.author Bessa Caserras, Xavier
• dc.contributor.author Carrión Rodríguez, José Antonio
• dc.date.accessioned 2022-09-14T06:48:33Z
• dc.date.available 2022-09-14T06:48:33Z
• dc.date.issued 2022
• dc.description.abstract Background: Nucleos(t)ide analogues withdrawal may improve HBsAg loss rates. However, conditions to select patients are not well established. Aims: to evaluate the impact of HBsAg kinetics before treatment interruption on post-treatment response. Methods: Longitudinal, ambispective study in non-cirrhotic chronic hepatitis B HBeAg-negative patients, analysing on-treatment and post-treatment HBsAg kinetics. On-treatment HBsAg kinetics diagnostic accuracy (AUROC) to identify HBsAg loss was evaluated. Results: 52 HBeAg-negative patients stopped treatment after 8.2 years, and 6 (11.5%) achieved HBsAg loss one year after withdrawal. Multivariate analysis showed that on-treatment HBsAg kinetics was related to HBsAg loss (OR=0.10; 95%CI=0.016-0.632; p = 0.014) with a high diagnostic accuracy (AUROC=0.935). A significant HBsAg decline ≥1 log10 IU/mL showed a positive and negative predictive value of 50% and of 97.6%, respectively. After treatment interruption, HBsAg decline speed (log10 IU/mL/year) accelerated in patients treated >6 years (from -0.06 to -0.20, p<0.05) and remained stable in treated <6 years (from -0.12 to -0.12 p=ns). Conclusions: On-treatment HBsAg kinetics can predict post-treatment HBsAg loss rate. Half of patients with a significant HBsAg decline can eliminate HBsAg the first year after withdrawal. Post-treatment HBsAg decline is faster not only in patients who lost the HBsAg but also in those who remain HBsAg-positive.
• dc.format.mimetype application/pdf
• dc.identifier.citation Broquetas T, Hernandez JJ, Garcia-Retortillo M, Canillas L, Puigvehí M, Cañete N, Coll S, Viu A, Garrido E, Mico M, Bessa X, Carrión JA. On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty. Dig Liver Dis. 2022 Aug;54(8):1044-51. DOI: 10.1016/j.dld.2021.12.017
• dc.identifier.doi http://dx.doi.org/10.1016/j.dld.2021.12.017
• dc.identifier.issn 1590-8658
• dc.identifier.uri http://hdl.handle.net/10230/54059
• dc.language.iso eng
• dc.publisher Elsevier
• dc.relation.ispartof Dig Liver Dis. 2022 Aug;54(8):1044-51
• dc.rights © 2022 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Antiviral
• dc.subject.keyword HBsAg
• dc.subject.keyword Hepatitis B
• dc.subject.keyword Kinetics
• dc.title On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion